AXSM News and Press, Axsome Therapeutics Inc. From 10/13/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock / Lane V. Erickson Social Security benefits are increasing for 2023 as the Social Security Administration announces an update to the Cost-of-Living Adjustment (COLA) . The COLA 2023 update will...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Today may be less than stellar for Relmada Therapeutics (NASDAQ: RLMD ), but it’s certainly a great day for Axsome Therapeutics (NASDAQ: AXSM ). Apparently, Relmada...

All the major U.S. indexes are in bear territory now, and many solid stocks have contributed to the market's downward tumble. But even during this rough year, some have been beating the market, and many of those outperformers can be found in the healthcare sector. Investors often favor that...

Averaging annual stock market returns of 10% or more is not easy to pull off, especially over a time horizon of at least five years. But with the right stocks, it is achievable. Of course, there are no guarantees in life or equity markets. It's essential to always follow investment best...

NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining the World Health Organization’s (WHO) 2022 World Mental...

Moderna (NASDAQ: MRNA) soared to fame in the early days of the pandemic thanks to its coronavirus vaccine. The stock price followed -- ending 2020 with a 434% gain. Since then, though, interest in vaccine stocks has waned. And Moderna shares have suffered. At the same time, ...

Axsome Therapeutics (NASDAQ: AXSM) has been making headlines for two reasons this year. First, the stock has defied the bear market. It has climbed 21% so far this year, while the S&P 500 index has dropped 20%. And second, the company is starting to sell its very first produ...

Citing payer dynamics ahead of its market launch, Bank of America painted a bleak outlook on Friday for Auvelity, a newly FDA-approved treatment for depression developed by Axsome Therapeutics ( NASDAQ: AXSM ). The firm retains the Overweight rating on the stock. The rapid...

The market looks scary this year, with the S&P 500 down 22%. Moreover, even the healthcare and biotech sectors -- considered defensive sectors in the equity markets -- have taken a beating. While the SPDR S&P Healthcare ETF is down 10% year to date, the SPDR S&am...

Summary Despite the recent downtrend in its trading, Axsome Therapeutics, Inc.'s fundamentals are stronger than ever. Asides from the Sunosi acquisition, the company recently gained Auvelity approval to treat major depressive disorder. Interestingly, the latest Type A meeting ...